Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
Open Access
- 1 August 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (8) , e2425581
Abstract
In 2020, esophageal cancer ranked sixth in mortality (544 100 deaths) worldwide.1,2 It consists of squamous cell carcinoma and adenocarcinoma. Esophageal and esophagogastric junction adenocarcinoma are considered a single entity, adenocarcinoma of the esophagogastric junction (AEG). The prognosis for patients with AEG undergoing upfront surgery has been poor. Five-year survival ranged from 36.9% for patients with node-negative disease to 9.6% for those with node-positive disease.2Keywords
This publication has 55 references indexed in Scilit:
- LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN studyAnnals of Oncology, 2023
- Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junctionEuropean Journal of Cancer, 2021
- Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA)Cochrane Database of Systematic Reviews, 2021
- Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trialEuropean Journal of Cancer, 2017
- Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs)European Journal of Surgical Oncology, 2017
- Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancersBritish Journal of Surgery, 2014
- Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate dataEuropean Journal of Cancer, 2013
- Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagusCochrane Database of Systematic Reviews, 2013
- Oesophageal cancer survival in Europe: A EUROCARE-4 studyCancer Epidemiology, 2012
- Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialEuropean Journal of Cancer, 2011